Loading organizations...
§ Private Profile · Sainte-hélène-du-lac, Rhone-Alpes, France
Supplier of customizable microcarriers for cell culture in bioreactors, optimizing yield and quality for cell and gene therapy biomanufacturing.
Carroucell is a biotechnology supplier that develops and manufactures customizable microcarriers for cell culture in bioreactors to optimize both yield and quality in cell and gene therapy production. The company provides specialized customization services to biomanufacturing clients, allowing them to precisely regulate complex bioreactor environments and improve overall manufacturing performance. Carroucell has collaborated with prominent research institutions such as the Etablissement Français du Sang to validate its proprietary microcarriers and secure its initial commercial orders. To scale its operations and expand its market reach, the enterprise secured €1.5 million in Series A funding led by the Novalis Biotech Acceleration fund. Additional participation in this financing round came from institutional backers including Crédit Agricole des Savoie and Bpifrance, alongside board member Jan Van den Berghe. Carroucell was founded in 2016 by its current President, Tarek Fathallah.
Carroucell has raised $1.5M across 1 funding round.
Carroucell has raised $1.5M in total across 1 funding round.
Carroucell has raised $1.5M in total across 1 funding round.
Carroucell's investors include Jan Van den Berghe, Bpifrance, Crédit Agricole.
Carroucell has raised $1.5M across 1 funding round. Most recently, it raised $1.5M Series A in September 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 7, 2022 | $1.5M Series A | JAN VAN DEN Berghe | Bpifrance, Crédit Agricole | Announced |